KLF11 and familial pancreatic carcinoma: However, in pancreatic cancer, oncogenic KRAS activates the ERK pathway, which, in turn, phosphorylates KLF11, and abrogates KLF11/SIN3a interaction, leading to transcriptional activation of SMAD7 and tumor progression.